Tiyo

R&D Sorrento a konsantre sou kondwi inovasyon nan COVID-19, tretman kansè, kontwòl total doulè ak maladi otoiminitè.

Pwogram kle yo Endikasyon Presiklik Faz I. Faz II Faz III/Pivotal FDA Apwobasyon
Pwogram COVID-19  

COVISTIX™ (dyagnostik) Rapid tès antijèn

*

Otorizasyon pou itilize ijans (EUA) nan Meksik (COFEPRIS), Brezil (ANVISA), ak CE make an Ewòp

COVIMARK™ (dyagnostik) Rapid tès antijèn

*

Aplikasyon yo te soumèt Ozetazini ak Kanada pou Otorizasyon Itilizasyon Ijans (EUA)

VIREX (dyagnostik) Dyagnostik lakay ou

60.2%*

EUA Enabling Studies in Q3 2022

COVISHIELD™ (tretman) Antikò netralize (IV) nan pasyan ekstèn ak pasyan ki entène

20%*

FUJOVEE™ (Abivertinib) Grav COVID-19 nan pasyan ICU

82%*

Pivotal Jijman annatant FDA Clearance

OQORY™ (COVI-MSC) ARDS akòz COVID-19 nan Pasyan ICU

82%*

Pivotal Jijman nan Brezil

Mpou Inibitè (grenn oral) Anti-viral

40%*

Vaksen mRNA Omicron Vaksen

20%*

Pwogram kle yo Endikasyon Presiklik Faz I. Faz II Faz III/Pivotal FDA Apwobasyon
imunoterapi  

FUJOVEE™ (Abivertinib) NSCLC

82%*

FUJOVEE™ (Abivertinib) Lenfom selil B

60.2%*

FUJOVEE™ (Abivertinib) Pwostat

20%*

FUJOVEE™ (Abivertinib) Loupous

20%*

FUJOVEE™ (Abivertinib) MS

20%*

FUJOVEE™ (Abivertinib) GvHD

20%*

PD-L1 (Socazolimab)* SCLC

82%*

*An patenarya ak Lee's Pharm nan peyi Lachin

PD-L1 (STI-3031)** Kansè nan matris

82%*

**Ozetazini ak an patenarya ak ImmuneOncia nan Kore di

CD47 Timè solid

40%*

CD38 DAR-T Plizyè myeloma

40%*

CD38 ADC Amyloidoz, miltip myeloma, T-ALL, ak èzofaj

40%*

Seprehvec™ viris onkolitik timè solid; Timè CNS

40%*

BCMA ADC Timè likid

20%*

Bevacizumab-ADNAB™ Endometrial Kansè

40%*

An patenarya ak Mayo Clinic

Bevacizumab-ADNAB™ Kansè ovè

40%*

An patenarya ak Mayo Clinic

Rituximab-ADNAB™ Lenfom selil B

40%*

An patenarya ak Mayo Clinic

Sofusa® anti-PD-1 Lenfom T-Selil Cutane (CTCL), Melanom

40%*

Pwogram kle yo Endikasyon Presiklik Faz I. Faz II Faz III/Pivotal FDA Apwobasyon
Doulè  

ZTlido® 1.8%
Postherpetic Neuralji - PHN

99.8%*

Gloerba®
Tretman pou gout (oral)

99.8%*

SEMDEXA (SP-102) Lonbèr Radikilè/Syatik Doulè

82%*

SP-103 (Lidokayin Topical System 5.4%) Doulè nan do

60.2%*

SP-104 (Reta Pete Dòz ba Naltrexone) Fibromyalji

20%*

RTX (resiniferatoxin)
Piki epidural
Doulè intractable nan kansè avanse

60.3%*

Deziyasyon òfelen

RTX (resiniferatoxin)
Wout Entra-artikulèr
Doulè OA nan jenou modere rive grav

60.2%*

Pwogram kle yo Endikasyon Presiklik Faz I. Faz II Faz III/Pivotal FDA Apwobasyon
Akouchman dwòg lenfatik  

Sofusa® anti-TNF Otoiminitè (RA)

40%*

Sofusa® anti-PD-1 Lenfom T-Selil Cutane (CTCL), Melanom

40%*

Sofusa® anti-CTLA-4 Melanoma

40%*

An patenarya ak Mayo Clinic
Pwogram COVID-19
Pwogram kle yo (Endikasyon) Faz
COVISTIX™ (dyagnostik) FDA USA
COVIMARK™ (dyagnostik) FDA USA
VIREX (dyagnostik) PH III
COVISHIELD™ (tretman) PH I
FUJOVEE™ (Abivertinib) Ph III
OQORY™ (COVI-MSC) Ph III
Mpou Inibitè (grenn oral) Ph II
Vaksen mRNA Omicron Presiklik
imunoterapi
Pwogram kle yo (Endikasyon) Faz
FUJOVEE™ (Abivertinib) Ph III
FUJOVEE™ (Abivertinib) Ph II
FUJOVEE™ (Abivertinib) Presiklik
FUJOVEE™ (Abivertinib) Presiklik
FUJOVEE™ (Abivertinib) Presiklik
FUJOVEE™ (Abivertinib) Presiklik
PD-L1 (Socazolimab)* Ph III
PD-L1 (STI-3031)** Ph III
CD47 (Timè Solid) Ph I
CD38 DAR-T (Miltip miltip) Ph I
CD38 ADC (Amyloidoz, miltip Myeloma, T-ALL, ak èzofaj) Ph I
Seprehvec™ viris onkolitik (Timè Solid; Timè CNS) PH I
BCMA ADC (Timè likid) Presiklik
Bevacizumab-ADNAB™ (Kansè andomèt) Ph I
Bevacizumab-ADNAB™ (Kansè ovè) Ph I
Rituximab-ADNAB™ (Lenfom selil B) Ph I
Sofusa® anti-PD-1 (Lenfom T-Selil Kutane (CTCL), Melanom) Ph I
Doulè
Pwogram kle yo (Endikasyon) Faz
ZTlido® 1.8% (Postherpetic Neuralji - PHN) FDA Apwobasyon
Gloerba® 1.8% Tretman pou gout (oral) FDA Apwobasyon
SEMDEXA (SP-102) Ph III
SP-103 (Lidokayin Topical System 5.4%) Ph II
SP-104 (Reta Pete Dòz ba Naltrexone) Presiklik
RTX (resiniferatoxin) Piki epidural Ph II
RTX (resiniferatoxin) Wout Entra-artikulèr Ph II
Akouchman lenfatik
Pwogram kle yo (Endikasyon) Faz II
Sofusa® anti-TNF (RA otoiminitè) Ph I
Sofusa® anti-PD-1 (Lenfom T-Selil Kutane (CTCL), Melanom) Ph I
Sofusa® anti-CTLA-4 (Melanom) Ph I